Europe

‘Life Science Panorama 2011’ report looks at France

Wednesday, May 23, 2012 11:13 AM

France Biotech, the French association of life science companies, in partnership with Ernst & Young, published the 10th annual “Life Science Panorama,” describing the industry's main trends for 2010-2011 in France and worldwide.

More... »


SGS acquires Vitrology

Wednesday, May 23, 2012 10:29 AM

SGS, a Swiss inspection, verification, testing and certification company, has decided to acquire Vitrology, a biopharmaceutical contract testing organization based in Glasgow, U.K.

More... »


Survey raises questions over NHS research

Tuesday, May 22, 2012 11:36 AM

A survey conducted by OnePoll on behalf of the National Institute for Health Research (NIHR) Clinical Research Network raises concerns that patients could be missing out on opportunities to take part in potentially beneficial clinical trials.

More... »

Wellcome Trust awards Phagenesis $1.5 million for dysphagia treatment

Tuesday, May 22, 2012 10:02 AM

Phagenesis, a U.K. company focused on dysphagia (the inability to swallow), has been awarded $1.5 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community.

More... »

GE Healthcare and Karolinska University to advance cell therapy

Tuesday, May 22, 2012 09:38 AM

Karolinska University Hospital Sweden, one of Europe's largest teaching hospitals, and GE Healthcare Life Sciences have formed a research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

More... »

PRA expands operations in the Netherlands and U.K.

Monday, May 21, 2012 03:48 PM

PRA, a global CRO, is expanding its operations in the Netherlands and the U.K. to accommodate staff growth and strong client demand for its phase IIa-IIIb service offerings.

More... »

Provence and Neuroptis collaborate on dry eye syndrome

Monday, May 21, 2012 01:03 PM

French companies Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, are strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate ML7 and producing the first GMP batches before the end of 2012.

More... »

Medivir appoints Juserius commercial executive vice president

Thursday, May 17, 2012 10:44 AM

Medivir, a Stockholm-based specialty pharmaceutical company focused on infectious diseases, has appointed Henric Juserius to head the company's commercial activities.

More... »

Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »

Marken acquires European kit building operation from LabCorp Clinical Trials

Friday, May 4, 2012 03:44 PM

Marken, a global clinical supply chain solutions provider, has acquired the European kit building operation from Laboratory Corporation of America Holdings through its LabCorp Clinical Trials division.

More... »

`

CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs